GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NaviFUS Corp (ROCO:6872) » Definitions » Additional Paid-In Capital

NaviFUS (ROCO:6872) Additional Paid-In Capital : NT$303.99 Mil(As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is NaviFUS Additional Paid-In Capital?


NaviFUS's quarterly additional paid-in capital increased from Dec. 2022 (NT$300.32 Mil) to Jun. 2023 (NT$301.71 Mil) and increased from Jun. 2023 (NT$301.71 Mil) to Dec. 2023 (NT$303.99 Mil).

NaviFUS's annual additional paid-in capital increased from Dec. 2021 (NT$298.81 Mil) to Dec. 2022 (NT$300.32 Mil) and increased from Dec. 2022 (NT$300.32 Mil) to Dec. 2023 (NT$303.99 Mil).


NaviFUS Additional Paid-In Capital Historical Data

The historical data trend for NaviFUS's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NaviFUS Additional Paid-In Capital Chart

NaviFUS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial 76.11 150.73 298.81 300.32 303.99

NaviFUS Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only 298.81 299.04 300.32 301.71 303.99

NaviFUS Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

NaviFUS Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of NaviFUS's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


NaviFUS (ROCO:6872) Business Description

Industry
Traded in Other Exchanges
N/A
Address
No.246, Sec 3, Chengde Road, 12th Floor, Datong District, Taipei City, TWN, 103
NaviFUS Corp is a Biotech company providing novel platform solutions for crossing the blood-brain barrier (BBB) for enhanced oncology drug delivery. Its product, the NaviFUS System, is designed to utilize non-invasive ultrasound energy to enable transient and safe enhancement of BBB permeability to facilitate the transport of small or large molecular CNS drugs to target tumor tissue at high precision for better treatment outcomes. Its vision is to cater to CNS disease patients locally and globally by bringing therapeutic ultrasound technology to clinical use.

NaviFUS (ROCO:6872) Headlines

No Headlines